Medication Management

NAPRA removes ephedrine and pseudoephedrine from National Drug Schedules
The move means that the National Association of Pharmacy Regulatory Authorities has now removed all products with Natural Product Number or Drug Identification Number-Homeopathic Medicine from the National Drug Schedules.
Executives of U.S. telehealth company accused of fraud that gave easy access to addictive Adderall drug
The actions of Done Global are alleged to have contributed to the ongoing shortage of ADHD medication.

Specialty medications: the AQPP requests class action suit against some of its members

In its appeal, the AQPP denounces an ‘opaque ecosystem for the distribution of specialty drugs’ which would harm the financial health of community pharmacies and patient safety.
‘A well-deserved trust’: Quebec pharmacists unanimous on Bill 67

Among the flagship measures tabled in Bill 67 is the power granted to pharmacists to do more tests and to prescribe and renew prescriptions indefinitely.
Celine Dion goes public with her private health struggles: What we’ve learned so far

The singer revealed that she took near-lethal doses of Valium to manage her symptoms before her diagnosis.
Give your pharmacy staff a checklist of steps for administering vaccines

Make sure all immunizers in your pharmacy are following key steps required for the aseptic preparation and administration of vaccines.
Tech presents CSHP webinar re Drug Access Navigators

The majority of DANs across Canada are pharmacy techs, especially given their understanding of drug billing.
The five most common e-prescribing errors: ISMP Canada

ISMP Canada found nearly 90 incidents linked to e-prescribing and community pharmacies over a five-year period.
Type 2 diabetes is not one-size-fits-all: Subtypes affect complications and treatment options

Although diabetes is broadly categorized into two main types, type 1 and type 2, each presents a diversity of subtypes, especially type 2 diabetes.
ALS drug Albrioza to be voluntarily withdrawn from the market in Canada

Phase 3 PHOENIX trial showed no significant benefit from Albrioza (sodium phenylbutyrate/ursodoxicoltaurine) compared to placebo.
Safety of combining PDE5 inhibitors and nitrates

Some studies have demonstrated lower mortality with phosphodiesterase-5 inhibitor treatment for erectile dysfunction in men with stable coronary artery disease, compared with no treatment.
Escape plans to save your clinical day

Here’s more advice to earlier career colleagues from Dr. Eric Cadesky.

NAPRA removes ephedrine and pseudoephedrine from National Drug Schedules

Executives of U.S. telehealth company accused of fraud that gave easy access to addictive Adderall drug

Specialty medications: the AQPP requests class action suit against some of its members

‘A well-deserved trust’: Quebec pharmacists unanimous on Bill 67

Celine Dion goes public with her private health struggles: What we’ve learned so far

Give your pharmacy staff a checklist of steps for administering vaccines

Tech presents CSHP webinar re Drug Access Navigators

The five most common e-prescribing errors: ISMP Canada

Type 2 diabetes is not one-size-fits-all: Subtypes affect complications and treatment options

ALS drug Albrioza to be voluntarily withdrawn from the market in Canada

Safety of combining PDE5 inhibitors and nitrates

Escape plans to save your clinical day